[go: up one dir, main page]

AU1269501A - Use of glp-1 agonists for the inhibition of beta cell degeneration - Google Patents

Use of glp-1 agonists for the inhibition of beta cell degeneration

Info

Publication number
AU1269501A
AU1269501A AU12695/01A AU1269501A AU1269501A AU 1269501 A AU1269501 A AU 1269501A AU 12695/01 A AU12695/01 A AU 12695/01A AU 1269501 A AU1269501 A AU 1269501A AU 1269501 A AU1269501 A AU 1269501A
Authority
AU
Australia
Prior art keywords
glp
agonists
inhibition
beta cell
cell degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12695/01A
Inventor
Soren Bregenholt
Richard David Carr
Carsten Foged Godtfredsen
Liselotte Bjerre Knudsen
Jacob Sten Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU1269501A publication Critical patent/AU1269501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU12695/01A 1999-11-12 2000-11-10 Use of glp-1 agonists for the inhibition of beta cell degeneration Abandoned AU1269501A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA199901628 1999-11-12
DKPA199901628 1999-11-12
DKPA200000270 2000-02-22
DKPA200000270 2000-02-22
PCT/DK2000/000625 WO2001035988A1 (en) 1999-11-12 2000-11-10 Use of glp-1 agonists for the inhibition of beta cell degeneration

Publications (1)

Publication Number Publication Date
AU1269501A true AU1269501A (en) 2001-05-30

Family

ID=26065974

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12695/01A Abandoned AU1269501A (en) 1999-11-12 2000-11-10 Use of glp-1 agonists for the inhibition of beta cell degeneration

Country Status (4)

Country Link
EP (1) EP1239871A1 (en)
JP (1) JP2003516322A (en)
AU (1) AU1269501A (en)
WO (1) WO2001035988A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
KR100458748B1 (en) 1998-12-07 2004-12-03 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Glp-1 analogues
CZ295890B6 (en) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application GLP-1 analogues having aminoisobutyric acid in position 8 and D-arginine in position 36, their use and pharmaceutical compositions in which the analogues are comprised
EP1634605A3 (en) * 2000-03-08 2006-10-11 Novo Nordisk A/S treatment of dyslipidemia in a patient having type 2 diabetes
DE60230818D1 (en) 2001-09-24 2009-02-26 Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY
JP2005516968A (en) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Combination use of GLP-1 compound and late diabetic complication modulator
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
JP2005535569A (en) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス GLP-1 agonists and cardiovascular complications
AU2003232172A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2007524579A (en) * 2003-02-19 2007-08-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Analogs of GLP-1
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2668951B9 (en) 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
CN105377306B (en) 2013-06-20 2020-03-17 诺和诺德股份有限公司 GLP-1 derivatives and uses thereof
AR096789A1 (en) * 2013-07-04 2016-02-03 Novo Nordisk As DERIVATIVES OF GLP-1 SIMILAR PEPTIDES AND USES OF THE SAME
CN106132985B (en) 2014-04-07 2020-10-13 诺和诺德股份有限公司 Diacylated GLP-1 Compounds
JP6730278B2 (en) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス GLP-1 derivative and use thereof
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
JP2001503963A (en) * 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー Diabetes treatment
KR100556067B1 (en) * 1996-08-30 2006-03-07 노보 노르디스크 에이/에스 Glp-1 derivatives
DE69911975T2 (en) * 1998-07-31 2004-09-09 Novo Nordisk A/S IN-VITRO STIMULATION OF BETA CELL REPRODUCTION
DE19921537A1 (en) * 1999-05-11 2000-11-23 Dieter Hoersch Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs

Also Published As

Publication number Publication date
EP1239871A1 (en) 2002-09-18
WO2001035988A1 (en) 2001-05-25
JP2003516322A (en) 2003-05-13

Similar Documents

Publication Publication Date Title
AU1269501A (en) Use of glp-1 agonists for the inhibition of beta cell degeneration
AU2001233622A1 (en) Inhibition of beta cell degeneration
AU2610599A (en) N-terminally truncated glp-1 derivatives
AU4850400A (en) The maize rs81 promoter and methods for use thereof
AU1367599A (en) Aromatic heterocyclic compounds as anti-inflammatory agents
AU3033500A (en) Non-peptide glp-1 agonists
AU1897700A (en) Removable stent
AU5994900A (en) Compounds for inhibiting diseases and preparing cells for transplantation
AU7751200A (en) Offset array adapter
AU1368300A (en) Cold-active beta galactosidase, the process for its preparation and the use thereof
AU1304601A (en) Solid preparations for oral use
AU5065999A (en) Naphthyridine derivatives
AU5056099A (en) Compounds for use in the treatment of inflammation
AU4457000A (en) In-barrel wetting screw charger
AU3682100A (en) Subsidiary materials for truss structure
AU3047299A (en) Methods of delivering glp-1
AU5787201A (en) Compounds active at the glucocorticoid receptor
AU6642900A (en) Improved materials for mycoculture
AUPP921299A0 (en) New heterocyclic compounds
AUPQ078799A0 (en) New use
AU2669501A (en) New use
AU5302100A (en) D-rings for braces
IL150128A0 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
AU6875800A (en) Heterocyclic compounds and process for the preparation thereof
AU6130299A (en) Use of mcrp for delivery of materials into cells

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase